Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer

NCT03344211 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03344211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03344211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 21, 2018
Completion date
December 31, 2027
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, prostate carcinoma metastatic in the bone, stage iv prostate cancer